A few weeks ago, our porphyria community received bad news. The U.S. Food and Drug Administration (FDA) issued a complete response letter to Disc Medicine’s new drug application for bitopertin, an experimental oral therapy designed to treat erythropoietic protoporphyria (EPP) or X-linked protoporphyria. This means the FDA rejected…
Hope in Action — Kristen Wheeden

Life changed for Kristen Wheeden when her youngest son, Brady, was diagnosed with erythropoietic protoporphyria in 2009. Kristen set out to learn as much as she could from both patients and doctors about porphyria. She has great hope for improved quality of life for patients living with porphyria, yet firmly believes that hope is ineffective without action. That is her motivation to act as a fierce advocate for porphyria patients and families and to support critical research. Hailing from Bethesda, Maryland, she enjoys life with her husband, three sons, and two dogs. Kristen serves as the president of the United Porphyrias Association.
Explore More Columns
Discussion
Discussion
Discussion
